Prof. K Dane Wittrup

Professor of Chemical Engineering and Bioengineering

Primary DLC

Department of Chemical Engineering

MIT Room: 76-261D

Areas of Interest and Expertise

Molecular Bioengineering
Protein Engineering Technology for Use in Developing Novel Biopharmaceuticals
Therapeutic Protein Biotechnology
Computational Biology
Molecular Pharmacology
Circulating Tumor Cells
Fluorescent Probes
Protein Interactions

Research Summary

The Wittrup Lab develops protein engineering technology and applies it to the discovery of new biopharmaceuticals. In particular, yeast surface display is used for the directed evolution of protein expression stability, affinity, and specificity. A particular focus is on the development of anti-cancer drugs, with quantitative studies of cellular-level pharmacokinetics and pharmacodynamics.

Engineers now have the tools to design biological products and processes at the molecular level. Proteins are of particular therapeutic interest, because proteins mediate most biochemical processes both inside and outside cells. The ability to manipulate the strength and specificity of protein binding events provides tremendous leverage for the development of novel biopharmaceuticals. We are developing powerful new tools for protein engineering, and applying them both to particular disease targets and to bettering our understanding of protein structure/function relationships. In the absence of predictive capabilities for protein design, a directed evolution or combinatorial library screening strategy can be effectively applied to alter protein properties in a desired fashion. We apply quantitative engineering analyses of the relevant kinetic and statistical processes to develop optimal search strategies on the protein "fitness landscape." In particular, we have developed a method for protein display on the surface of yeast cells that, for example, enabled engineering of a noncovalent protein-ligand bond with a dissociation half-time over one week. We are engineering potential protein biopharmaceuticals in areas where molecular understanding of disease pathology is sufficient to hypothesize particular objective functions to target. For example, antibodies can be used to target cell-killing modalities to cancerous cells, given sufficiently strong and specific binding properties. Growth factors that carry signals between cells do so via particular binding events that, if manipulated to alter intracellular trafficking or signalling outcomes, could alter immune responses in precisely defined ways. Finally, viral and nonviral vectors for gene therapy could be targeted to specific cells and tissues via alteration of an exchangeable antibody recognition module. Altered proteins developed in this work can also provide a potential vehicle for new insights into the mechanisms of protein-ligand binding. We are performing biophysical analyses of the kinetic, thermodynamic, and structural aspects of engineered protein function in order to contribute to an improved understanding of protein binding processes.

Recent Work